Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico

Detalhes bibliográficos
Ano de defesa: 2024
Autor(a) principal: Costa, Ana Georgina Oliveira Pontes
Orientador(a): Ayala, Alejandro Pedro
Banca de defesa: Não Informado pela instituição
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Não Informado pela instituição
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Área do conhecimento CNPq:
Link de acesso: http://repositorio.ufc.br/handle/riufc/77259
Resumo: The pharmaceutical industry is one of the sectors of great worldwide relevance nowadays, for its prominence in the production of the medicines so necessary for the cure and prevention of several diseases and the co-crystallization arouses great interest in this sector. Control and understanding of the physical-chemical characteristics of the solid state of Active Pharmaceutical Ingredients (API) is an important part of the process of developing new drugs. To meet this demand, there is an urgent need for continuous research and optimization of production processes. Starting from this premise, crystal engineering applied to drugs aims to develop new structural designs through the strategic utilization of supramolecular synthons. This strategy that uses crystal engineering aims to improve the physicochemical properties of drugs, such as stability, solubility, bioavailability, dissolution, among others. In view of the above, in the present work, studies were conducted with Secnidazole (SNZ), a potent antimicrobial applied worldwide in the treatment of neglected diseases, aiming at the possibility of obtaining new designs of this drug, with the objective of overcoming the inherent stability challenges imposed by its hemi-hydrated form. Based on extensive research in the literature and after carrying out a meticulous screening of molecular interaction, through the method of slow evaporation crystallization and grinding between SNZ and a significant number of coformers, unprecedented co-crystals were synthesized with Fumaric Acid (FMA) and with 3,5-dinitrobenzoic Acid (DNZ), which were characterized by single-crystal X-ray diffraction employing synchrotron radiation and complemented with data from infrared spectroscopy and powder X-ray diffraction. Furthermore, multicomponent compounds of SNZ with other coformers were obtained, such as succinic acid, citric acid, oxalic acid, thymol, and salicylic acid, which were also characterized by powder X-ray diffraction. In conclusion, this study significantly advanced the understanding of cocrystal formation involving secnidazole through systematic investigation and characterization of new solid forms. Therefore, it constitutes a contribution of significant relevance and alternative with the possibility of positively impacting the health of patients using this API, since the investment of the pharmaceutical industry in the research, development and optimization of drugs applied worldwide in the treatment of neglected diseases remains limited.
id UFC-7_efaaa8f855a42a5bcd5f4ff16b281c51
oai_identifier_str oai:repositorio.ufc.br:riufc/77259
network_acronym_str UFC-7
network_name_str Repositório Institucional da Universidade Federal do Ceará (UFC)
repository_id_str
spelling Costa, Ana Georgina Oliveira PontesAyala, Alejandro Pedro2024-07-15T16:35:27Z2024-07-15T16:35:27Z2024COSTA, Ana Georgina Oliveira Pontes. Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico. 2024. Tese (Doutorado em Desenvolvimento e Inovação Tecnológica em Medicamentos) – Faculdade de Farmácia, Odontologia e Enfermagem, Universidade Federal do Ceará, Fortaleza, 2024. Disponível em: http://www.repositorio.ufc.br/handle/riufc/ 77259 Acesso em: 15 jul. 2024.http://repositorio.ufc.br/handle/riufc/77259The pharmaceutical industry is one of the sectors of great worldwide relevance nowadays, for its prominence in the production of the medicines so necessary for the cure and prevention of several diseases and the co-crystallization arouses great interest in this sector. Control and understanding of the physical-chemical characteristics of the solid state of Active Pharmaceutical Ingredients (API) is an important part of the process of developing new drugs. To meet this demand, there is an urgent need for continuous research and optimization of production processes. Starting from this premise, crystal engineering applied to drugs aims to develop new structural designs through the strategic utilization of supramolecular synthons. This strategy that uses crystal engineering aims to improve the physicochemical properties of drugs, such as stability, solubility, bioavailability, dissolution, among others. In view of the above, in the present work, studies were conducted with Secnidazole (SNZ), a potent antimicrobial applied worldwide in the treatment of neglected diseases, aiming at the possibility of obtaining new designs of this drug, with the objective of overcoming the inherent stability challenges imposed by its hemi-hydrated form. Based on extensive research in the literature and after carrying out a meticulous screening of molecular interaction, through the method of slow evaporation crystallization and grinding between SNZ and a significant number of coformers, unprecedented co-crystals were synthesized with Fumaric Acid (FMA) and with 3,5-dinitrobenzoic Acid (DNZ), which were characterized by single-crystal X-ray diffraction employing synchrotron radiation and complemented with data from infrared spectroscopy and powder X-ray diffraction. Furthermore, multicomponent compounds of SNZ with other coformers were obtained, such as succinic acid, citric acid, oxalic acid, thymol, and salicylic acid, which were also characterized by powder X-ray diffraction. In conclusion, this study significantly advanced the understanding of cocrystal formation involving secnidazole through systematic investigation and characterization of new solid forms. Therefore, it constitutes a contribution of significant relevance and alternative with the possibility of positively impacting the health of patients using this API, since the investment of the pharmaceutical industry in the research, development and optimization of drugs applied worldwide in the treatment of neglected diseases remains limited.A indústria farmacêutica é um dos setores de grande relevância mundial na atualidade, tendo em vista sua proeminência no que tange à produção dos medicamentos tão necessários para a cura e a prevenção de diversas enfermidades e a cocristalização desperta grande interesse nesse setor. O controle e o entendimento das características físico-químicas do estado sólido dos Insumos Farmacêuticos Ativos (IFA) é uma importante parte do processo de desenvolvimento de novos medicamentos. Para atender a essa demanda, é premente a necessidade de pesquisa contínua e otimização dos processos de produção. Partindo dessa premissa, a engenharia de cristais aplicada a fármacos tem o propósito de desenvolver novos designs estruturais através da utilização estratégica dos synthons supramoleculares. Essa estratégia que utiliza a engenharia de cristais visa ao aprimoramento das propriedades físico-químicas e biofarmacêutica dos fármacos, tais como, a estabilidade, a solubilidade, a biodisponibilidade, a dissolução, dentre outras. Diante do exposto, no presente trabalho, foram realizados estudos com o Secnidazol (SNZ), um potente antimicrobiano aplicado mundialmente no tratamento de doenças negligenciadas, visando à possibilidade de obtenção de novos designs desse fármaco, com o objetivo de superar os desafios de estabilidade inerentes, impostos por sua forma hemihidratada. Com base em extensa pesquisa na literatura e após realização de minuciosa triagem da interação molecular, pelo método de cristalização por evaporação lenta e moagem entre o SNZ e um número expressivo de coformadores, foram sintetizados cocristais inéditos com o Ácido Fumárico (FMA) e com o Ácido 3,5-dinitrobenzóico (DNZ), os quais foram caracterizados por meio da difração de raios X em monocristal empregando radiação síncrotron e complementada com dados provenientes da espectroscopia no infravermelho e difração de raios X em pó. Ademais, foram obtidos compostos multicomponentes de SNZ com outros coformadores, tais como, o ácido succínico, ácido cítrico, ácido oxálico, timol e ácido salicílico, os quais também tiveram sua caracterização realizada por meio de difração de raios X em pó. Em conclusão, este estudo avançou significativamente a compreensão da formação de cocristais envolvendo o secnidazol através da investigação sistemática e caracterização de novas formas sólidas. Portanto, constitui uma contribuição de relevância significativa com possibilidade de impactar positivamente a saúde dos pacientes em uso desse IFA, uma vez que o investimento da indústria farmacêutica na pesquisa, no desenvolvimento e na otimização dos medicamentos aplicados mundialmente no tratamento de doenças negligenciadas ainda permanece limitado.Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêuticoinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisSecnidazolCristalizaçãoDifração de Raios XSecnidazoleCrystallizationX-Ray DiffractionCNPQ::CIENCIAS DA SAUDE::FARMACIAinfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da Universidade Federal do Ceará (UFC)instname:Universidade Federal do Ceará (UFC)instacron:UFChttps://orcid.org/0000-0002-4093-1884http://lattes.cnpq.br/3081087692723161https://orcid.org/0000-0002-9247-6780http://lattes.cnpq.br/0589484713269268ORIGINAL2024_tese_agopcosta.pdf2024_tese_agopcosta.pdfTeseapplication/pdf3697582http://repositorio.ufc.br/bitstream/riufc/77259/1/2024_tese_agopcosta.pdf9d3ad43aef0078080c675ca5f4e2e39dMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repositorio.ufc.br/bitstream/riufc/77259/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53riufc/772592024-07-15 13:36:22.189oai:repositorio.ufc.br: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Repositório InstitucionalPUBhttp://www.repositorio.ufc.br/ri-oai/requestbu@ufc.br || repositorio@ufc.bropendoar:2024-07-15T16:36:22Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)false
dc.title.pt_BR.fl_str_mv Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico
title Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico
spellingShingle Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico
Costa, Ana Georgina Oliveira Pontes
CNPQ::CIENCIAS DA SAUDE::FARMACIA
Secnidazol
Cristalização
Difração de Raios X
Secnidazole
Crystallization
X-Ray Diffraction
title_short Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico
title_full Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico
title_fullStr Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico
title_full_unstemmed Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico
title_sort Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico
author Costa, Ana Georgina Oliveira Pontes
author_facet Costa, Ana Georgina Oliveira Pontes
author_role author
dc.contributor.author.fl_str_mv Costa, Ana Georgina Oliveira Pontes
dc.contributor.advisor1.fl_str_mv Ayala, Alejandro Pedro
contributor_str_mv Ayala, Alejandro Pedro
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS DA SAUDE::FARMACIA
topic CNPQ::CIENCIAS DA SAUDE::FARMACIA
Secnidazol
Cristalização
Difração de Raios X
Secnidazole
Crystallization
X-Ray Diffraction
dc.subject.ptbr.pt_BR.fl_str_mv Secnidazol
Cristalização
Difração de Raios X
dc.subject.en.pt_BR.fl_str_mv Secnidazole
Crystallization
X-Ray Diffraction
description The pharmaceutical industry is one of the sectors of great worldwide relevance nowadays, for its prominence in the production of the medicines so necessary for the cure and prevention of several diseases and the co-crystallization arouses great interest in this sector. Control and understanding of the physical-chemical characteristics of the solid state of Active Pharmaceutical Ingredients (API) is an important part of the process of developing new drugs. To meet this demand, there is an urgent need for continuous research and optimization of production processes. Starting from this premise, crystal engineering applied to drugs aims to develop new structural designs through the strategic utilization of supramolecular synthons. This strategy that uses crystal engineering aims to improve the physicochemical properties of drugs, such as stability, solubility, bioavailability, dissolution, among others. In view of the above, in the present work, studies were conducted with Secnidazole (SNZ), a potent antimicrobial applied worldwide in the treatment of neglected diseases, aiming at the possibility of obtaining new designs of this drug, with the objective of overcoming the inherent stability challenges imposed by its hemi-hydrated form. Based on extensive research in the literature and after carrying out a meticulous screening of molecular interaction, through the method of slow evaporation crystallization and grinding between SNZ and a significant number of coformers, unprecedented co-crystals were synthesized with Fumaric Acid (FMA) and with 3,5-dinitrobenzoic Acid (DNZ), which were characterized by single-crystal X-ray diffraction employing synchrotron radiation and complemented with data from infrared spectroscopy and powder X-ray diffraction. Furthermore, multicomponent compounds of SNZ with other coformers were obtained, such as succinic acid, citric acid, oxalic acid, thymol, and salicylic acid, which were also characterized by powder X-ray diffraction. In conclusion, this study significantly advanced the understanding of cocrystal formation involving secnidazole through systematic investigation and characterization of new solid forms. Therefore, it constitutes a contribution of significant relevance and alternative with the possibility of positively impacting the health of patients using this API, since the investment of the pharmaceutical industry in the research, development and optimization of drugs applied worldwide in the treatment of neglected diseases remains limited.
publishDate 2024
dc.date.accessioned.fl_str_mv 2024-07-15T16:35:27Z
dc.date.available.fl_str_mv 2024-07-15T16:35:27Z
dc.date.issued.fl_str_mv 2024
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv COSTA, Ana Georgina Oliveira Pontes. Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico. 2024. Tese (Doutorado em Desenvolvimento e Inovação Tecnológica em Medicamentos) – Faculdade de Farmácia, Odontologia e Enfermagem, Universidade Federal do Ceará, Fortaleza, 2024. Disponível em: http://www.repositorio.ufc.br/handle/riufc/ 77259 Acesso em: 15 jul. 2024.
dc.identifier.uri.fl_str_mv http://repositorio.ufc.br/handle/riufc/77259
identifier_str_mv COSTA, Ana Georgina Oliveira Pontes. Obtenção e caracterização de cocristais de secnidazol: uma abordagem promissora da engenharia de cristais no setor farmacêutico. 2024. Tese (Doutorado em Desenvolvimento e Inovação Tecnológica em Medicamentos) – Faculdade de Farmácia, Odontologia e Enfermagem, Universidade Federal do Ceará, Fortaleza, 2024. Disponível em: http://www.repositorio.ufc.br/handle/riufc/ 77259 Acesso em: 15 jul. 2024.
url http://repositorio.ufc.br/handle/riufc/77259
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da Universidade Federal do Ceará (UFC)
instname:Universidade Federal do Ceará (UFC)
instacron:UFC
instname_str Universidade Federal do Ceará (UFC)
instacron_str UFC
institution UFC
reponame_str Repositório Institucional da Universidade Federal do Ceará (UFC)
collection Repositório Institucional da Universidade Federal do Ceará (UFC)
bitstream.url.fl_str_mv http://repositorio.ufc.br/bitstream/riufc/77259/1/2024_tese_agopcosta.pdf
http://repositorio.ufc.br/bitstream/riufc/77259/3/license.txt
bitstream.checksum.fl_str_mv 9d3ad43aef0078080c675ca5f4e2e39d
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)
repository.mail.fl_str_mv bu@ufc.br || repositorio@ufc.br
_version_ 1847793359498772480